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Abstract
Contagious disease is a major threat to survival, and the cost of relying on the immune system to
defeat pathogens is high; therefore, behavioral avoidance of contagious individuals is arguably an
adaptive strategy. Animal findings demonstrate the ability to detect and avoid sick individuals by
the aid of olfactory cues, and a recent study indicated that human axillary odor also becomes more
aversive as a function of immune activation. By injecting healthy human participants with lipopolysaccharide (0.6 ng/kg body weight) to experimentally induce inflammation, this study demonstrates that natural daily rhythms of urine odor—its perceived dimensions and volatile profile—are
altered within hours of inflammation onset. Whereas healthy human urine decreases in averseness
over the course of a single day, inflammation interrupts this process and results in an increased
urine odor averseness and an altered volatile composition. These results support the notion that
subtle and early cues of sickness may be detected and avoided, thereby complementing the immune system in its role of keeping us alive and healthy.
Key words: behavioral immune system, human, inflammation, odor, sickness, urine

Introduction
Throughout evolution, one of the more common causes of death
has been infections (Jones et al. 2012). The threat posed by infection for living organisms is reflected in the fact that genes related
to immunity are evolutionary hotspots, with pathogens as a leading
cause of change in humans (Fumagalli et al. 2011). Recent evidence
suggests that selective pressures have also shaped a behavioral defense against disease (Schaller and Duncan 2007). Indeed, across
phyla, behavior adjustment would represent a first line of defense
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against infection, preventing or reducing parasite load via the detection of sickness cues and the initiation of avoidance behaviors
(Curtis 2014), as well as sickness behaviors, to increase recuperation
once infected (Dantzer et al. 2008).
It is becoming increasingly clear that most mammals—including humans—rely on olfaction for communication (Wyatt 2014).
Among the cues communicated by endogenous volatile compounds
are an individual’s age (Osada et al. 2003; Mitro et al. 2012), genetic composition (Eggert et al. 1998), kin status (Lundstrom et al.
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2009), and emotional state (de Groot et al. 2012). In addition, a
number of nonhuman animal studies have demonstrated that urine
from immune-activated individuals contains volatile sickness cues
and that these cues initiate an avoidance response in conspecifics
(Kavaliers and Colwell 1995a, 1995b; Kiesecker et al. 1999; Ehman
and Scott 2001, 2002; Arakawa et al. 2011; Kimball et al. 2014).
The variety of immune challenges used in these studies, from parasites to viruses, including vaccines, suggests that the mechanisms
regulating the release of such communicative volatile metabolites are
not necessarily disease-specific. Furthermore, although these volatile
cues could be generated at any stage of the innate or adaptive immune responses, their rapid availability post-administration, within
hours of pathogen exposure, appears to exclude adaptive immunity.
The quick-acting, general, innate immune response, therefore, is a
strong contender for regulating such cues (Kimball et al. 2014).
A common experimental model of the innate immune system’s
acute inflammatory response utilizes injection of the bacterial endotoxin lipopolysaccharide (LPS), a potent, nonspecific activator of the
innate immune system (Dantzer et al. 2008; Beutler 2009). Toll-like
receptor 4 (TLR4), expressed on sentinel cells, recognizes and binds
LPS, resulting in the production of interleukin-1β (IL-1β) pro-inflammatory cytokines. Thereafter, IL-1β triggers its own synthesis as well
as that of additional, mainly pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and anti-inflammatory cytokines, such as interleukin-10 (IL-10) (Karshikoff 2015).
This inflammatory cascade peaks and subsides within 4–6 h of LPS
injection. Rodents injected with LPS are perceptually discriminable
to conspecifics from their saline-injected counterparts, as evidenced
by increased avoidance behavior (Renault et al. 2008; Arakawa et al.
2009). Furthermore, smelling only the soiled bedding of LPS- versus
saline-injected conspecifics evoked a similar heightened avoidance
response, indicating that detectible odor cues of acute inflammation
are present in the urine volatile profile (Arakawa et al. 2009, 2010;
Boillat et al. 2015). Further support for the causal role of innate immune activation in the generation of this aversive odor cue comes
from data demonstrating that infusion of pro-inflammatory IL-1β
was sufficient to induce this heightened avoidance response and that
infusion of anti-inflammatory IL-10 was sufficient to suppress it
(Arakawa et al. 2010). Together, these studies demonstrate that nonhuman animals are capable of detecting cues of inflammation—not
just infection—from the urine odors of conspecifics.
Evidence for a human capacity to communicate and detect conspecific sickness cues comes to a large extent from observational research and anecdotal reports that infectious and metabolic diseases
emit disease-specific odor profiles (Penn and Potts 1998; Shirasu and
Touhara 2011). However, these reports do not exemplify the inflammation detection necessary for successful behavioral avoidance of
infected conspecifics but rather detection of more advanced disease
states. Moreover, these data are often confounded by selection biases
involving diet, lifestyle, and medication factors that may also affect
endogenous odor (Parma et al. 2017). To bypass such confounds,
we previously used an experimental LPS model of acute inflammation in otherwise healthy individuals to demonstrate that humans—
like other mammals—are able to detect cues of acute inflammation.
Participants found the axillary odors of human conspecifics collected during LPS-induced inflammation to be significantly more
unpleasant, intense, and unhealthy than those collected from the
same individuals after injection with a saline placebo (Olsson et al.
2014). Furthermore, we recently demonstrated that such axillary olfactory sickness cues were processed by a cortical network including
primary and secondary olfactory areas in the brain and tended to
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reduce the likability of simultaneously presented faces (Regenbogen
et al. 2017). Thus, axillary odor cues can provide information on
the inflammatory status in humans, but whether similarly detectable
cues exist in human urine odor is not yet known.
Studies of nonhuman animals have assessed the changes in endogenous odor caused by acute inflammation and the behavioral effects they induce in conspecifics using, with few exceptions, urine—a
volatile source seldom studied in humans. The numerous anatomical
and cultural adaptations that separate modern Homo sapiens from
primates and even from earlier members of our own species have
limited the contexts in which (and diminished the frequency with
which) humans encounter conspecifics’ urine. However, although the
value to modern humans of any cue in conspecific urine odor may be
limited, the presence or absence of a detectable cue with the potential to mediate avoidance is an independent question. Knowledge of
the selection pressures favoring disease avoidance, the demonstrated
ability of nonhuman animals to detect inflammation in urine volatiles, and the relatively recent shared ancestry of these animals and
humans, in parallel with knowledge of the demonstrated human
ability to detect inflammation in conspecific axillary volatiles and of
the fact that the profile of volatile compounds in human urine overlaps significantly with that emitted by the human axillae (Penn et al.
2007), make human urine a promising potential source for cues of
inflammation.
The aims of this study were 2-fold: first, we sought to determine
whether humans can detect an acute inflammatory response in urine
volatiles; second, we sought to identify potential volatile markers of
the acute inflammatory response. Donors were injected with either
LPS or a saline placebo, and urine was collected both before and
after injection. To facilitate a double-blind design, we opted to use a
low dose of LPS to induce a systemic increase in pro-inflammatory
cytokines while minimizing overt behavioral and physical symptoms of sickness. The odor of urine samples was assessed by healthy
human participants to identify perceptual differences induced by LPS
treatment. Samples were also analyzed chemically by gas chromatography–mass spectrometry (GC-MS) to identify changes in volatile metabolites with the potential to discriminate LPS from Placebo
treatments. We hypothesized that the changes to urine odor and
volatile profile induced by LPS and Placebo treatment would be discriminable by perceptual and chemical assays, respectively, thereby
indicating that human urine contains detectable cues of acute inflammation with the potential to mediate behavioral avoidance.

Materials and methods
Endotoxin treatment and sample collection (urine
and plasma) from donors
Thirty-three healthy volunteers participated as urine donors after
providing informed written consent, 20 in the LPS condition (13
women) and 13 in the Placebo condition (8 women). Donors were
right-handed, medication-free, nonsmokers without any history of
drug abuse, chronic pain, or psychiatric disorders. All women were
premenopausal, and usage of hormonal contraceptives was allowed.
Beginning 12 h prior to the first sample collection, donors followed
a restricted diet free of food known to scent urine. Treatment and
sample collection (urine and plasma) were performed using a randomized, double-blind, between-subjects design under the supervision of an attending physician in a hospital environment (Karshikoff
et al. 2015). An injection of either 0.6 ng LPS/kg body weight
(Escherichia coli, Lot nr. G3E0609; United States Pharmacopeia)
or phosphate-buffered saline solution was delivered intravenously
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at approximately 10:00 AM. Selection of a low LPS dosage facilitated maintenance of the double-blind design for the duration of the
subsequent sample collection period. Urine samples were collected
from each donor approximately 1 h pre- and 4 h postinjection in
plastic cups and then immediately transferred to glass storage vials.
The time elapsed between pre- (Pre) and postinjection urine sample
(Post) collections did not differ significantly between conditions,
t(23.49) = 0.42, P = 0.677 (LPS: 4.5 ± 0.8 h; Placebo: 4.4 ± 0.8 h).
Plasma samples were collected from each donor preinjection (baseline, 0 h) and at 1.5, 3.5, and 5 h postinjection in 10 mL ethylenediaminetetraacetic acid (EDTA) plasma tubes (BD Vacutainer) and
were cold centrifuged at 1500 × g for 20 min. Urine and plasma
samples were frozen at −70 °C on location immediately after collection and thawed 1 h before usage in either the chemical or behavioral assay. Urine samples were kept in freezers at −70 °C for the
entirety of the 2.25–2.75 year storage period between collection and
analysis, except for the duration of express shipment to the United
States, during which they were kept frozen on dry ice. All aspects of
the treatment and sample collection portions of the experiment were
approved by the Regional Ethical Review Board and performed at
the Karolinska University Hospital (Solna, Sweden) in accordance
with the Declaration of Helsinki on biomedical studies involving
human subjects.

Measures of an inflammatory response in donors
Plasma samples were analyzed using the MILLIPLEX MAP high-sensitivity human cytokine kit (Millipore Corporation) with Luminex
xMAP methodology (Luminex Corporation). Levels of TNF-α, IL-6,
IL-8, and IL-10 were measured at each collection time, and the area
under the curve (AUC) was calculated for each cytokine to verify
the presence and absence of an inflammatory response in LPS and
Placebo donors, respectively.

Sensory assessment participants
Twenty-one participants (13 women, 26.2 ± 3.6 years, range:
19–32 years) performed the sensory assessment portion of the experiment after providing informed written consent. Participants
were medication-free nonsmokers without any history of consciousness loss resulting from head trauma or hormonal, autoimmune, neurological, or psychiatric disorders–all factors with the
potential to affect olfactory processing (Boesveldt et al. 2011). To
verify that no participant had functional anosmia, a 6-item, 4-alternative, forced-choice odor identification test, selected from the
original 40-item Monell Extended Sniffin’ Sticks Identification Test
(MONEX-40) (Freiherr et al. 2012), was administered. All participants correctly identified 4 or more odors, corresponding to a binomial probability significantly better than chance (P < 0.05). On
the day of testing, participants used no scented body products and
refrained from chewing gum and eating or drinking anything but
water for the hour immediately prior to testing. All aspects of the
sensory assessment portion of the experiment were approved by the
institutional review board of the University of Pennsylvania and performed at the Monell Chemical Senses Center (Philadelphia, United
States) in accordance with the Declaration of Helsinki on biomedical
studies involving human subjects.

Sensory assessment of donor urine samples
Sensory testing was performed in rooms engineered for odor testing,
equipped with a high air exchange rate to prevent lingering odors and
red fluorescent lighting to prevent potential differences in stimulus
color from influencing sensory assessments. Urine from 27 donors,
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15 LPS (11 women, 26.5 ± 6.0 years, range: 20.6–41.0 years) and 12
Placebo (7 women, 27.6 ± 4.9 years, range: 20.5–35.2 years), was used
in the sensory assessment portion of the experiment as, due to suspicion of contamination (e.g., noncompliance with food and hygiene
instructions), urine from 6 donors was excluded. Donor age did not
differ significantly between conditions [t(24.97) = 0.51, P = 0.612].
(Routine outlier identification in the GC-MS data later indicated that
there were no outliers among the urine samples from 4 of the 6 excluded donors, and these were subsequently included in the chemometric analyses.) For sensory assessment, urine samples from LPS and
Placebo donors were divided into multiple stimulus “triplets,” each
comprising 1 Post and 2 identical Pre volumes of 1.0 mL urine in
20 mL glass vials. Urine samples were vortexed before aliquoting
to prevent any effects of sample fractionation. Each participant performed the same perceptual ratings and discrimination tasks on 3 LPS
triplets (9 vials) and 3 Placebo triplets (9 vials) in 2 counterbalanced
blocks of the testing session. In other words, each participant smelled
Pre and Post urine samples from 3 LPS and 3 Placebo donors of the
same sex. Stimulus triplets were pseudorandomly assigned to a participant and were never reused for any other participant.
In the 3-alternative, forced-choice discrimination tasks, participants were instructed to, on each of 11 trials, choose the odd
one out of the 3 vials of a donor triplet, 1 vial with a donor’s Post
urine sample (target) and 2 with the same donor’s Pre urine samples
(lures). Trial order was pseudorandomized among the 3 donor triplets, either LPS or Placebo, depending on the experimental block,
such that 2 of the 3 triplets were used on 4 trials, each, and 1 of the 3
triplets was used on only 3 of the 11 trials. Using intra-donor triplets
precluded the possibility of discrimination based on donor identity,
at which humans are adept (Lundström et al. 2008, 2009), rather
than treatment, thereby preventing a sizeable confound.
Perceptual ratings of odor pleasantness, intensity, disgustingness,
and donor sickness were performed on visual analog scales (VAS).
Perceived odor pleasantness is widely believed to be the primary dimension of olfactory perceptual space and may be the basis of olfactory functioning (Yeshurun and Sobel 2010). Perceived intensity was
chosen to assess the contribution of a quantitative, as opposed to
qualitative, treatment-induced change in urine odor, and perceived
disgust was selected on the basis of its hypothesized evolution as a
disease-avoidance mechanism (Oaten et al. 2009). Duplicate ratings
were collected in 2 rounds, each with a unique randomized order
of vials from the 3 stimulus triplets of that block. Rating scales for
perceived intensity, disgustingness, and sickness ranged from 0 to 10,
and the minima and maxima were defined as “Not at all” and “Most
imaginable,” respectively. The scale for perceived pleasantness ratings ranged from −5 to 5, defined as “Most unpleasant imaginable”
and “Most pleasant imaginable,” respectively, and it contained a
midpoint defined as “Neutral.”

Chemometric analyses of donor urine samples
Headspace GC-MS and subsequent chromatographic data analyses assessed the potential differences in the profiles of volatile (i.e.,
odorous) organic compounds of urine from 33 LPS and Placebo
donors. Triplicate 25 µL urine aliquots from each donor were transferred to individual 20 mL glass sample vials and fortified with
10 µL of an aqueous l-carvone solution so that 80.2 ng was precisely
delivered to each sample. Control samples consisted of “blank”
vials, all of which lacked urine and contained only the aqueous lcarvone solution. All samples were subjected to headspace analysis
using a HT3 dynamic headspace analyzer (Teledyne Tekmar) outfitted with Supelco Trap K Vocarb 3000 thermal desorption trap
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(Sigma-Aldrich). Each sample vial was maintained at 40 oC and
swept with helium for 45 min (flow rate of 75 mL/min), and the
volatiles were collected on the trap. Trap contents were desorbed
at 265 oC directly into an ISQ single quadrupole GC-MS (Thermo
Scientific) equipped with a 30 m × 0.25 mm I.D. Stabilwax-DA
fused-silica capillary column (Restek). The GC oven program had an
initial temperature of 40 oC (held for 3.0 min) followed by a ramp
of 7.0 oC/min to a final temperature of 230 oC (held for 6.0 min).
The mass spectrometer was used in scan mode from 33 to 400 m/z.
Chromatographic data were converted to NetCDF format for
baseline correction, noise elimination, and peak alignment using
MetAlign (Lommen 2009). Resulting multivariate data (consisting
of all mass spectrometric responses exceeding a predefined threshold
at each scan event) were further processed with the MSClust tool
for mass spectra extraction and generation of individual selected ion
chromatogram peak responses (Tikunov et al. 2012). Peak responses
were scaled to the response of l-carvone, the internal standard. The
resulting data set, arising from 201 urine sample analyses, consisted
of a single scaled response per chromatographic peak identified in
the headspace, which were submitted to statistical analyses.

further analysis. Samples from 31 donors were retained—19 donors
from the LPS condition (13 women, 26.1 ± 5.6 years, range: 20.1–
41.1 years) and 12 donors from the Placebo condition (7 women,
27.6 ± 4.9 years, range: 20.5–35.2 years). Donor age did not differ
significantly between conditions [t(25.87) = 0.77, P = 0.446]. Among
retained sample data, means from repeated chemical analyses of the
same urine sample were calculated for each carvone-scaled peak
response. Treatment differences were calculated for each donor by
subtracting mean Pre responses from mean Post responses. To reduce
the number of variables for analysis, the VARCLUS procedure in SAS
was used to group the 42 difference responses into related clusters.
Component scores were then calculated from VARCLUS scoring coefficients and standardized differences using the SCORE procedure
(SAS). Seven component scores were subjected to multivariate analysis of variance with univariate ANOVA to determine which clusters were impacted by treatment (the lone between-subjects effect).
The individual chemical variables contributing to significant clusters
were identified. Standardized mean peak responses for these individual chemical variables were submitted to LMEM analyses constructed with Treatment (LPS and Placebo) and Time (Pre and Post)
as fixed effects and Donor identity as a random effect.

Statistical analyses and data handling
Analyses were performed in R 3.0.2 (R Development Core Team
2013) using the lme4 package (Bates et al. 2015) for LMEM and
multcomp package (Hothorn et al. 2008) for subsequent post hoc
t-tests. P values below 0.05 were considered statistically significant.
Cytokine data
Successful activation of the immune system by LPS injection in urine
donors was assessed using AUC measures. Between-treatment (LPS
and Placebo) comparisons were carried out for each cytokine with
2-sided Welch’s t-tests. These analyses were conducted on the larger
group of donors included in chromatographic analyses (n = 31). Due
to technical problems, plasma samples from 1 donor were missing
(n = 30; 18 LPS, 12 Placebo).
Perceptual discrimination data
Discriminability of Pre and Post urine was compared between LPS
and Placebo treatments using a paired t-test of mean number of correct trials.

Results
Verification of an inflammatory response in donors
Successful triggering of the innate immune system was demonstrated by significant LPS-induced increases in AUC measures
of plasma cytokine concentrations, relative to Placebo: TNF-α,
t(17.122) = 4.21, P = 0.0006; IL-6, t(17.184) = 4.393, P = 0.0004;
IL-8, t(17.043) = 3.697, P = 0.0018; and IL-10, t (17.319) = 5.24,
P < 0.0001 (Figure 1).

Perceptual discrimination
Results from the discrimination tasks (Figure 2) indicated that the
perceptual discriminability differed significantly between treatments
[LPS = 4.24 correct trials ± standard deviation 1.87, 38.5 ± 17.0%;
Placebo = 5.71 ± 1.76, 51.9 ± 16.0%; t(20) = 2.62, P = 0.016], with
participants correctly discriminating Post from Pre in more Placebo
than LPS trials.

Perceptual ratings
Perceptual ratings data
To assess the effects of treatment on perceived dimensions of urine
odor, linear mixed-effects models (LMEM) were constructed with
Treatment (LPS and Placebo) and Time (Pre and Post) as fixed effects and Participant and Donor identity as random effects, which
accounted for inter-participant differences in rating behavior and
inter-donor differences in endogenous odor. One participant who
misunderstood the rating procedure for perceived disgust was excluded from that model. All perceptual VAS ratings were natural
log-transformed before analysis, and statistical results are reported
in linear terms.
Chromatographic data
All carvone-scaled peak responses were subjected to principal components analysis using Unscrambler (CAMO Software) to visually
identify outlier samples exhibiting undue influence or leverage in residual plots. Nine of the 201 samples were identified as outliers, and
removal of these resulted in an absence of any posttreatment samples for 2 donors, thereby effectively excluding those donors from

A significant interaction of Treatment (LPS and Placebo) and Time
(Pre and Post) on perceived urine odor intensity, χ2(1) = 5.64,
P = 0.018, was mirrored by a statistical trend for perceived donor
sickness, χ2(1) = 3.33, P = 0.068, but not for odor disgustingness,
χ2(1) = 2.61, P = 0.106, and pleasantness, χ2(1) = 0.19, P = 0.666
(Figure 3). The nominal pattern of results suggests that the natural
decrease in urine odor averseness observed in Placebo donors over
the day was disrupted by LPS treatment, rendering postinjection LPS
samples more aversive than their Placebo counterparts.
As the correlations between the 4 types of ratings were high (absolute values between 0.52 and 0.80), a factor analysis was conducted,
indicating a single factor solution (absolute factor loadings between
0.69 and 0.92). A factor score—indicating levels of intensity, pleasantness, disgust, and donor sickness—was calculated for each trial.
Another analysis, like that described earlier, revealed a significant
interaction of Treatment and Time on the factor score, χ2(1) = 4.36,
P = 0.037. In accordance with the results above, the factor score
tended to decrease from the Pre- to the Post-measurement, but less
so for LPS-treated participants (Figure 4).
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Figure 1. Levels of cytokines (pg/ml). Error bars denote standard error of the mean.

Chemometric analysis
Urine samples were submitted to chemical analysis and subsequent chromatographic data processing to assess the pattern
of treatment effects on the volatile profile. Cluster analysis revealed 7 clusters, ranging from 22 compounds to 2 compounds.
Analysis of cluster scores indicated that there was a significant
treatment effect for only 1 of the 7 clusters (P = 0.015). The
3 odorants comprising this cluster were chromatographic peaks
identified by comparison to known standards as: acetophenone,
pyrrole, and benzaldehyde. Analysis with LMEM revealed significant or statistical trends for the interaction of Treatment
(LPS and Placebo) and Time (Pre and Post) for acetophenone,
χ2(1) = 10.79, P = 0.001; pyrrole, χ2(1) = 8.75, P = 0.003; and
benzaldehyde, χ2(1) = 3.08, P = 0.079. In short, pyrrole and
acetophenone were significantly more abundant following LPS
treatment, as indicated by Figure 5.

Discussion

Figure 2. Number of correct discriminations of Pre and Post urine for LPS
and Placebo samples. Error bars denote standard error of the mean, and the
asterisk indicates significance (*P < 0.05).

The results presented here suggest that within hours of exposure to
even a relatively weak immune challenge, acute inflammation can
induce changes to human urine odor that are detectable by both
human and chemical assays.
More specifically, the results revealed a natural rhythm—a pattern over time—of decreasing urine odor averseness through the day
(from morning [Pre] to midday [Post] collections), a change that is
disrupted by upregulation of the innate immune system. The time
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course of this natural rhythm, observed in Placebo urine, is unsurprising given the well-established facts that the kidneys’ glomerular filtration rate decreases overnight and increases during the
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day (Koopman et al. 1989) and that a significant proportion of the
human urine metabolome exhibits a diurnal rhythm (Giskeødegård
et al. 2015).

Figure 3. Perceptual ratings of Pre and Post urine for LPS and Placebo samples. Error bars denote standard error of the mean, the asterisk indicates significance
(*P < 0.05). The scales for ratings range from 0 “Not at all” to 10 “Most imaginable,” with the exception of the scale for pleasantness, which ranges from −5 “Most
unpleasant imaginable” to 5 “Most pleasant imaginable.”

Figure 4. The factor score—reflecting a hypothesized latent variable for levels of intensity, pleasantness, disgust, and donor sickness—for Pre and Post urine for
LPS and Placebo samples. Error bars denote standard error of the mean, and the asterisk indicates significance (*P < 0.05).
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Figure 5. Differences between Pre- and Post-measurements of carvone-normalized pyrrole concentrations and acetophenone concentrations in LPS- and
Placebo-treated urine. Error bars denote standard error of the mean, AU refers to arbitrary units of differences, and asterisks indicate significance (*P < 0.05,
**P < 0.01, ***P < 0.001).

Although it remains to be conclusively demonstrated what mediated the difference in discriminability of Pre and Post urine between
the healthy, Placebo and LPS treatments, our chemometric data and
perceptual ratings offer enticing clues. In the absence of inflammation, the chemometric data revealed a natural decrease in pyrrole
abundance from Pre to Post collection times—a change sufficient
for linear discriminant models to differentiate Post from Pre Placebo
urine. This decrease in pyrrole abundance was absent under LPS
treatment. The perceptual ratings may reflect this natural drop of
pyrrole abundance in the decrease of perceived intensity observed
posttreatment for Placebo, but not LPS, samples (Figure 3). This suggests that pyrrole may be a urinary volatile with a diurnal rhythm
that is interrupted by activation of the innate immune system, resulting in higher-than-normal pyrrole levels in Post LPS urine samples. LPS did induce a significant change in the urinary volatile
profile in the form of increased acetophenone abundance. No such
change in acetophenone abundance was seen in Placebo samples,
suggesting that this increase is because of treatment alone rather
than to any natural rhythmic changes.
By what mechanism(s) inflammation alters endogenous odor volatiles is not well known (Arakawa et al. 2011), especially not for
the time scale investigated here (hours). The innate immune system,
which is reliably activated by the canonical stimulus LPS, has repeatedly been linked to endogenous odors both in animals (Beauchamp
et al. 1985; Beauchamp and Yamazaki 2005; Arakawa et al. 2010)
and in humans (Olsson et al. 2014), but whether the effects demonstrated in this study are directly mediated by inflammatory processes
cannot be conclusively demonstrated. However, the 2 odorous volatiles, pyrrole and acetophenone, that were significantly elevated as
a function of LPS have previously been suggested as biomarkers for
various diseases and pathogen infections. The metabolite pyrrole has
been identified as elevated in the metabolic disorder phenylketonuria disorder (Burke et al. 1983). Increases in urine concentrations of
acetophenone have previously been indicated in the mouse models of
lung cancer (Matsumura et al. 2010). How elevated levels of pyrrole
and acetophenone and activation of the immune system are linked is
currently not clear. However, based on their known involvement in
different pathologies, it is conceivable that these 2 odorous volatiles
together enabled discrimination between treatments in the cluster

model, not as disease- or pathogen-specific cues but rather as indicators of the general inflammatory response.
An understanding of the perception of health—or sickness—as
a complex process of integrating multiple sensory cues, often from
multiple sensory modalities, is important for appreciating the role
that even the smallest cues can play in contributing to the differentiation of sick and healthy conspecifics. We have demonstrated an
additive effect of olfactory–visual integration in the perception of
sickness cues from facial photographs and body odors (Regenbogen
et al. 2017). And we recently demonstrated (Axelsson et al. 2018)
that health perception is influenced by a number of subtle visual cues
of inflammation—such as paleness of the skin and lips, redness of the
eyes, and droopiness of the eyelids. With knowledge of the role that
sensory integration plays in health perception, it becomes easier to
appreciate the potency of disease detection—even during the early
stages of inflammation when cues may be weak.
These results, akin to animal findings, indicate that there is an
olfactory cue of inflammation in human urine detectable to conspecifics. The perceived differences of urine odor intensity, sickness, and
disgustingness indicate that we find the urine of other humans hours
after onset of an inflammatory response more aversive than the urine
of healthy counterparts at the same time of day, when baseline (Pre)
measures are corrected for. The relative differences in abundances of
pyrrole and acetophenone, and in discriminability between Placebo
and LPS urine, offer tantalizing glimpses into, respectively, the potential chemical mechanisms that may underpin and the potential
behavioral consequences that may rest on these perceptual differences. However, these data do not provide causal links between the
chemical changes, perceived changes, and discriminability changes.
Future studies, based on these results, can bridge these knowledge gaps and refine our description of this inflammation cue
in human urine by optimizing and narrowing the scope of their
experimental designs. The putative volatile mediators identified here, pyrrole and acetophenone, can be targeted directly in
follow-up studies, thereby avoiding data reduction practices.
To help mitigate the potential for urine concentration to bias
between-treatment perceptual or chemometric measures, future
studies should standardize hydration levels among their urine
donors. These data, however, appear unaffected by this confound,
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as the chemometric analyses failed to demonstrate any general
shift in abundancy as a function of LPS treatment. Limiting the
effects of urine sample preservation by minimizing the handling
of samples between collection and analysis would also strengthen
the results of future studies.
The results of this study strengthen the rising view that systemic
inflammation entails physiological changes that are perceptually detectable to other humans, possibly serving adaptive purposes during
evolution as a behavioral defense against infectious disease, a central
threat to survival.
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